Glioblastoma (GBM) is the most common and most aggressive primary brain tumor in adults. On standard chemoradiation, median progression-free survival has historically been 4.0-6.9 months and median overall survival 14.6-17.0 months. The blood-brain barrier keeps most peptide drugs out of the brain, because they are too large or too polar to cross it.
Sapience Therapeutics' lucicebtide (ST101), a first-in-class peptide antagonist of the transcription factor C/EBPβ, reached brain tumors with confirmed uptake and target engagement. In a small Phase 2 study of 9 evaluable patients with newly diagnosed GBM who also received standard chemoradiation, Sapience projected a median progression-free survival of 28.4 months as of an April 27, 2026 cutoff, and it presented updated data at ASCO 2026 on June 1. That figure was compared with historical results, not with a placebo group.
The first randomized peptide readout in GBM this year was mixed. On October 7, 2026, MimiVax and Roswell Park reported that SurVaxM, a peptide-mimic vaccine against the survivin protein, missed its overall survival goal in the 233-patient Phase 2b SURVIVE trial in newly diagnosed GBM: median survival was 22.8 months versus 20.3 months on placebo (p=0.076). In a prespecified group of patients 65 and under, median survival was 24.2 versus 20.2 months, a result that needs confirmation in another trial.
See #lucicebtide, #cancer-vaccine, and #blood-brain-barrier.
In an abstract for the Society for Neuro-Oncology meeting, Duke researchers reported that 18 adults with newly diagnosed MGMT-unmethylated glioblastoma received up to seven doses of P30-EPS after radiation. The vaccine links cytomegalovirus pp65, survivin, and EphA2 peptides to a tetanus toxoid epitope, and was given with the immune stimulant Hiltonol. All treatment-related side effects were grade 2 or lower, 11 patients showed antigen-specific T-cell responses, and median progression-free and overall survival were 9.7 and 15.3 months in this single-arm study.
Oncopeptides reported on October 9, 2026 that in the open-label INSULA window-of-opportunity study at Oslo University Hospital, active drug was found in resected tumor tissue from the first three patients with recurrent glioblastoma given melflufen, its EMA-approved peptide-drug conjugate, before surgery, meeting the study's primary goal of showing the drug crosses the blood-brain barrier. The company said tumor drug levels matched what animal studies predicted but gave no numbers, and the study is not designed to show clinical benefit. It plans to enroll about 10 patients and will discuss the data in an investor webcast on October 12.
MimiVax and Roswell Park Comprehensive Cancer Center reported on October 7, 2026 that in SURVIVE, a randomized, double-blind, placebo-controlled Phase 2b trial in 233 evaluable patients with newly diagnosed glioblastoma at 11 U.S. centers, adding SurVaxM to standard treatment gave a median overall survival of 22.8 months versus 20.3 months on placebo (hazard ratio 0.75, p=0.076), short of statistical significance. In a prespecified group of patients 65 and under, median survival was 24.2 versus 20.2 months (hazard ratio 0.64, p=0.019), and about 42% versus 18% were alive at 30 months or later. SurVaxM is a peptide-mimic vaccine aimed at survivin, a protein found in about 95% of glioblastomas; grade 3 or higher side effects occurred in 48% versus 46% of patients, and MimiVax plans to ask the FDA about faster approval routes.
At ASCO 2026, Sapience Therapeutics presented updated Phase 2 data for lucicebtide (ST101), a first-in-class peptide antagonist of the transcription factor C/EBPβ, now studied in 125 patients. In newly diagnosed glioblastoma plus standard of care, projected median PFS reached 28.4 months and median OS was not yet reached, with 6 of 9 patients alive beyond 22.3 months. Spatial transcriptomics confirmed on-target activity through negative enrichment of the C/EBPβ regulon and suppression of mesenchymal transformation, with no dose-limiting toxicities or related serious adverse events.
Dana-Farber Cancer Institute researchers led by David Reardon (Director, Center for Neuro-Oncology) and Catherine Wu (Chief, Division of Stem Cell Transplantation and Cell Therapies) presented Phase 1 data at ASCO 2026 on NeoVax — a personalized neoantigen peptide vaccine — combined with pembrolizumab in newly diagnosed glioblastoma. The study excluded dexamethasone (an immune suppressant) and added pembrolizumab to enhance anti-tumor activity. Vaccine-stimulated anti-tumor activity was still evident in some patients after one year, with vaccine-specific T cells migrating into the brain and tumors following vaccination. The MGMT-methylated patient subgroup showed median survival meaningfully exceeding historical observations, though the authors emphasized this requires cautious interpretation given the lack of a randomized comparator arm. The timing of pembrolizumab administration didn't affect immune-response stimulation, but pembrolizumab-before-NeoVax-priming may extend overall survival. NeoVax adds to the personalized neoantigen vaccine cohort (BioNTech autogene cevumeran, Moderna intismeran autogene, Evaxion EVX-01) anchoring the broader peptide cancer vaccine field.
Sapience Therapeutics' May 21 ASCO 2026 data update on lucicebtide (ST101) — a first-in-class C/EBPβ peptide antagonist — included a specific data point worth surfacing for the Tuesday cycle. In the Phase 2 Window-of-Opportunity study (n=9 evaluable as of April 27 data cutoff), patients with newly diagnosed glioblastoma (ndGBM) treated with lucicebtide plus standard-of-care chemoradiation achieved a projected median progression-free survival of 28.4 months — meaningfully exceeding the 4.0-6.9 month historic benchmark range. Six of nine patients remain alive past 22.3 months against a historical median OS range of 14.6-17.0 months. Median overall survival has not yet been reached. Lucicebtide crossed the blood-brain barrier with confirmed tumor uptake and target engagement via negative enrichment of the C/EBPβ regulon in tumor and myeloid cells. The poster session is scheduled for Monday June 1.
Sapience Therapeutics announced May 22 positive Phase 2 clinical and pharmacodynamic data update from its lucicebtide (ST101) trial in glioblastoma ahead of the ASCO 2026 Annual Meeting (May 29-June 2 Chicago). The Phase 2 Window-of-Opportunity study evaluates lucicebtide alone and in combination with standard-of-care chemoradiation, with dosing both before and after surgical resection. Nine patients were evaluable for analysis; the maturing data show durable progression-free and overall-survival improvements with a well-tolerated safety profile. Lucicebtide is a first-in-class peptide antagonist of CCAAT/enhancer-binding protein β (C/EBPβ) — a transcription factor that drives tumor aggressiveness, immune evasion, and stemness in glioblastoma. The 125-patient program across recurrent GBM monotherapy and newly diagnosed combination cohorts is the largest peptide-mechanism dataset in GBM to date. The Monday June 1 poster session details the efficacy, pharmacodynamics, and safety in newly-diagnosed patients.
Recent reviews and real-world observation studies aggregate the state of peptide-vaccine immunotherapy for glioblastoma. A 2024 Nature Communications real-world observational study reported clinically meaningful outcomes for personalized peptide vaccines; the UCPVax + temozolomide trial (NCT04280848) showed 97% anti-TERT immune response, 48% epitope spread, median OS 17.9 months, and 26% alive at 2 years. The peptide-vaccine modality is one of multiple approaches (mRNA, dendritic cell, neoantigen) advancing alongside immune checkpoint blockade.